{"id":"surufatinib-gemcitabine-nab-paclitaxel","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"},{"rate":"5-20%","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing cancer cells. Nab-paclitaxel is a formulation of paclitaxel that targets cancer cells by disrupting microtubule function, leading to cell cycle arrest and apoptosis.","oneSentence":"Surufatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:02.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced pancreatic neuroendocrine tumors"},{"name":"Advanced malignant pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07436741","phase":"PHASE3","title":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02","conditions":"Pancreatic Cancer, Adult","enrollment":106},{"nctId":"NCT05908747","phase":"PHASE2","title":"Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-31","conditions":"Pancreatic Cancer","enrollment":29},{"nctId":"NCT06361888","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-05-08","conditions":"Metastatic Pancreatic Cancer","enrollment":502},{"nctId":"NCT05481476","phase":"PHASE2","title":"Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-12-12","conditions":"Pancreatic Neoplasms","enrollment":32},{"nctId":"NCT05969171","phase":"PHASE2","title":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-05","conditions":"Pancreatic Cancer Metastatic","enrollment":65},{"nctId":"NCT05218889","phase":"PHASE1, PHASE2","title":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2021-08-04","conditions":"Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer","enrollment":90},{"nctId":"NCT05832892","phase":"PHASE1, PHASE2","title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-11-01","conditions":"Unresectable Locally Advanced or Metastatic Pancreatic Cancer","enrollment":41},{"nctId":"NCT06378580","phase":"","title":"The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Luo Cong","startDate":"2022-07-01","conditions":"Pancreatic Cancer","enrollment":72},{"nctId":"NCT06361030","phase":"PHASE2","title":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-06-01","conditions":"Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"surufatinib + gemcitabine + nab-paclitaxel","genericName":"surufatinib + gemcitabine + nab-paclitaxel","companyName":"Tianjin Medical University Cancer Institute and Hospital","companyId":"tianjin-medical-university-cancer-institute-and-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Surufatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). Used for Advanced pancreatic neuroendocrine tumors, Advanced malignant pancreatic cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}